Ginkgo Bioworks (DNA) Q1 Revenues Beat; Guides Higher
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Ginkgo Bioworks Reports First Quarter 2022 Financial Results
May 16, 2022 4:01 PM EDT$168 million of Total revenue in Q1 2022, representing an increase of 282% over Q1 2021
11 new Cell Programs added in Q1 2022, representing 175% growth over Q1 2021
Increasing full year guidance for Total revenue from $325Â $340 million to $375 $390 million, reiterating Foundry revenue guidance and increasing Biosecurity revenue guidance
Recently announced plans to expand platform capabilities in agricultural biologicals through a series of M&A transactions and flagship collaboration with Bayer
$1.5 billion cash balance provides meaningful multi-year runway as we drive towards... More
